Synthaverse SA
SVE
Company Profile
Business description
Synthaverse SA is a global pharmaceutical company. Its goal is to provide the best, innovative and unique solutions for medicine. Its work is based on scientific and health knowledge. Along with its expert approach, it allows the company to create reliable and unique products. It manufactures one of the few drugs used internationally in the oncological immunotherapy of bladder cancer.
Contact
10, Uniwersytecka street
Lublin20-029
POLT: +48 815338221
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
237
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
stocks
Our top ASX picks in every sector
These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks
Tesla: Shares fall as deliveries come in below consensus
Long-term growth less reliant on auto sales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,167.50 | 3.80 | 0.04% |
| CAC 40 | 7,908.74 | 53.65 | -0.67% |
| DAX 40 | 22,921.59 | 246.49 | -1.06% |
| Dow JONES (US) | 46,584.46 | 85.42 | -0.18% |
| FTSE 100 | 10,348.79 | 87.50 | -0.84% |
| HKSE | 25,781.65 | 665.12 | 2.65% |
| NASDAQ | 22,017.85 | 21.51 | 0.10% |
| Nikkei 225 | 56,151.13 | 2,721.57 | 5.09% |
| NZX 50 Index | 13,294.85 | 225.19 | 1.72% |
| S&P 500 | 6,616.85 | 5.02 | 0.08% |
| S&P/ASX 200 | 8,959.70 | 13.10 | -0.15% |
| SSE Composite Index | 3,939.79 | 49.62 | 1.28% |